China’s NHC to Assume Management of Human Genetic Resources from May 2024
The National Health Commission (NHC) of China has announced that the State Council has approved...
Policy / Regulatory
Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly...
Hubei Province Issues Anti-Commercial Bribery Guidelines for Medical Industry
The Hubei provincial market supervision administration has released a set of guidelines titled “Anti-Commercial Bribery...
China Unveils 16-Measure Policy to Support Overseas Investment in Domestic Tech Firms
A coalition of 10 Chinese government bureaus, including the Ministry of Commerce, Ministry of Foreign...
China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises
The China Securities Regulatory Commission (CSRC) has introduced a comprehensive set of 16 measures aimed...
China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value
The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in...
China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration
The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...
China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders
Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based...
China’s CDE Issues Guidelines for Pediatric Drug Labeling Updates
China’s Center for Drug Evaluation (CDE) has issued a notice outlining the “Detailed Rules for...
China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds
The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court,...
Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance
The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court,...
China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...
China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan
The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...
EU Set to Investigate China’s Medical Device Procurement Practices Amid Fairness Concerns
The European Union (EU) is reportedly gearing up to launch an investigation into medical device...
FDA Advisory Committee Backs MRD as Accelerated Approval Endpoint for Multiple Myeloma
The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) has...
Hainan Medical Zone Launches ‘Lecheng Global Special Medical Insurance’ for Wider Drug Access
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has launched the “Lecheng Global Special...
NHSA Reports 2023 Milestones in Basic Medical Insurance Participation and Financials
The National Healthcare Security Administration (NHSA) has published its annual “Healthcare Security Development Statistical Bulletin”...
BIO’s Chief Lobbyist Nick Shipley Resigns Amid Controversy Over WuXi AppTec
Nick Shipley, the chief lobbyist for the U.S.-based Biotechnology Innovation Organization (BIO), has resigned from...
Shanghai Health Commission Implements Strict Guidelines to Curb Medical Sector Misconduct
The Shanghai Municipal Health Commission has issued the “Implementation Rules for the Nine Guidelines for...
China’s CDE Issues Guidelines for Semaglutide Biosimilar Clinical Trials with Weight Management Focus
The Center for Drug Evaluation (CDE) in China has released a new set of Guidelines...